Ocera Therapeutics, Inc.
OCRX
OCRX was delisted on the 8th of December, 2017.
31 hedge funds and large institutions have $21.3M invested in Ocera Therapeutics, Inc. in 2016 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 4 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
45% more capital invested
Capital invested by funds: $14.7M → $21.3M (+$6.58M)
6% less funds holding
Funds holding: 33 → 31 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VMI
VHCP Management II
New York
|
+$350K |
| 2 |
PVI
Pura Vida Investments
New York
|
+$295K |
| 3 |
VM
VHCP Management
New York
|
+$150K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$54.4K |
| 5 |
Renaissance Technologies
New York
|
+$41.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$199K |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$68K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$60K |
| 4 |
TI
Turner Investments
Berwyn,
Pennsylvania
|
-$13.2K |
| 5 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
-$7.48K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BIM
26
BlackRock Investment Management
Wilmington,
Delaware
| $7K | +$944 | +378 | +16% |
|
27
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $5K | – | – | – |
|
28
Morgan Stanley
New York
| $3K | – | – | – |
|
|
TRCT
29
Tower Research Capital (TRC)
New York
| $1K | +$142 | +57 | +17% |
|
30
Bank of America
Charlotte,
North Carolina
| $1K | +$894 | +358 | +261% |
|
31
JP Morgan Chase
New York
| $1K | +$999 | +400 | New |
|
|
GTC
32
Ghost Tree Capital
New York
| – | -$68K | -35,801 | Closed |
|
33
UBS Group
Zurich,
Switzerland
| – | -$2K | -1,040 | Closed |
|
OCRX Hedge Fund Activity: Q3 2016 in Review
31 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Ocera Therapeutics, Inc. (OCRX) for Q3 2016, worth a combined $21.3M — up 45% from $14.7M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of OCRX and 2 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 10 added.
The largest buyer was VHCP Management II, adding an estimated $350K. The largest seller was Bridgeway Capital Management, cutting an estimated $199K.
- 31 institutional investors held Ocera Therapeutics, Inc. (OCRX) as of Q3 2016, down from 33 in Q2 2016.
- Funds reported $21.3M of Ocera Therapeutics, Inc. stock for Q3 2016, up 45% quarter-over-quarter.
- 2 funds opened new Ocera Therapeutics, Inc. positions in Q3 2016 and 4 closed out, a net change of -2 holders.
- The largest Ocera Therapeutics, Inc. buyer in Q3 2016 was VHCP Management II, an estimated $350K added.
- The largest Ocera Therapeutics, Inc. seller in Q3 2016 was Bridgeway Capital Management, an estimated $199K sold.
Based on aggregated 13F filings for Q3 2016.